Response to: 'Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al' by Notz et al

Ann Rheum Dis. 2022 Nov;81(11):e217. doi: 10.1136/annrheumdis-2020-218795. Epub 2020 Nov 25.
No abstract available

Keywords: B-lymphocytes; Covid-19; antirheumatic agents; lupus erythematosus; rituximab; systemic.

Publication types

  • Comment

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • COVID-19 Drug Treatment*
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / drug therapy

Substances

  • Antirheumatic Agents
  • Hydroxychloroquine